Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2024 07:00 ET | Source: Eisbach Bio GmbH

Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors

The first patient has been dosed in Eisbach Bio’s Phase 1/2 MATCH clinical trial at MD Anderson assessing the ALC1 inhibitor EIS-12656 in solid tumors.